Skip to main content

Bicara Therapeutics Inc.

corporate_fare Company Profile

Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed BCAX - Latest Insights

BCAX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
8
Bicara Therapeutics Reports Increased Losses Amid Pivotal Phase 3 Trial Advancement and Strong Cash Runway
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:59 AM EDT
Source: Reuters
Importance Score:
7
Bicara Therapeutics Reports Q4 Net Loss of $37.4M, Confirms Phase 3 Trial Initiation
Sentiment: Neutral
View Wiseek Article
BCAX
Mar 30, 2026, 7:47 AM EDT
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Initiates Pivotal Phase 3 Trial and Secures $161.8M in Oversubscribed Offering, Extending Cash Runway to 2029
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Bicara Therapeutics Kicks Off Phase 3 Trial for FORTIFI-HN01, Targeting Year-End Enrollment
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:25 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
RA Capital Management Invests $40M in Bicara Therapeutics Public Offering, Boosting Stake to 11.5%
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:22 PM EST
Filing Type: 4
Importance Score:
8
RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants
Sentiment: Positive
View Wiseek Article
BCAX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Bicara Therapeutics Closes $161.8M Public Offering, Bolstering Cash for Drug Development
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 25, 2026, 9:50 PM EST
Filing Type: 424B5
Importance Score:
8
Bicara Therapeutics Finalizes $150M Public Offering of Common Stock and Warrants at Discount
Sentiment: Negative
View Wiseek Article
BCAX
Feb 24, 2026, 9:47 PM EST
Filing Type: FWP
Importance Score:
8
Bicara Therapeutics Amends Public Offering to Include Pre-Funded Warrants for $150M Capital Raise
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
7
Bicara Therapeutics Announces $150M Public Offering to Fund Pipeline Advancement
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 19, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Reports Positive Phase 1b Data for Ficerafusp Alfa in HNSCC, Plans New Dosing Regimen
Sentiment: Positive
View Wiseek Article
BCAX
Jan 12, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Selects Optimal Phase 3 Dose for Lead Drug, Aligns with FDA, and Outlines 2026 Growth Strategy
Sentiment: Positive
View Wiseek Article